Financial Data and Key Metrics Changes - Revenue for the nine-month period was just over JPY 3.4 trillion, a decrease of 3.3% or -2.8% at constant exchange rate [11] - Core Operating Profit was JPY 971.6 billion, a year-on-year decrease of 3.4% at both actual effects and constant exchange rate [11] - Reported operating profit was JPY 422.4 billion, an increase of 1.2% [12] - Core EPS was JPY 428, and reported EPS was JPY 137 [12] - Adjusted free cash flow was JPY 625.9 billion, even after a $1.2 billion upfront payment to Innovent Biologics [12] Business Line Data and Key Metrics Changes - Growth and launch products represented over 50% of total revenue and grew 6.7% at constant exchange rate [12] - In GI, Entyvio grew 7.4% at constant exchange rate, with strong growth in Q3 due to a one-time gross-to-net drop [12][13] - Takhzyro in rare diseases slowed to 2.4% growth at constant exchange rate, impacted by new competing products in the U.S. [13] - Immunoglobulin growth was 4.3% year to date, driven by subcutaneous IG products [14] - Qdenga growth accelerated to 22.1%, primarily driven by Brazil [14] Market Data and Key Metrics Changes - Entyvio Pen is now on the formulary with all three large pharmacy benefit managers, achieving commercial coverage of more than 80% [13] - The impact of Medicare Part D redesign in the U.S. has affected IVIG sales, which are expected to normalize in Q4 [14] - Albumin growth returned to 1.3%, slower than expected due to softening demand in China [14] Company Strategy and Development Direction - The company is preparing for significant new product launches, focusing on oveporexton, rusfertide, and zasocitinib, expected to launch over the next 18 months [6][9] - The late-stage pipeline includes eight programs with the potential to transform the standard of care [10] - The company is committed to maintaining operational efficiency while investing in R&D for future growth [17] Management's Comments on Operating Environment and Future Outlook - Management revised revenue guidance to low single-digit decline at constant exchange rate due to stronger than anticipated Vyvanse generic erosion [18] - The company maintains full-year guidance for core operating profit and core EPS, emphasizing cost discipline [18] - Management expressed confidence in the potential of new product launches to drive future growth despite current challenges [20][41] Other Important Information - This earnings call marked Christophe Weber's last as a main presenter, with Julie Kim set to take over as CEO [29] - The company is undergoing organizational changes to enhance competitiveness and speed in preparation for multiple launches [31][55] Q&A Session Summary Question: Thoughts on next fiscal year and dividend policy - Management indicated it is too early to provide guidance for the next fiscal year, with the budget being finalized [39] - The company aims to maintain a progressive dividend policy, evaluating core EPS and cash flow to decide on potential increases [42] Question: Zasocitinib phase II outcomes and safety data - Data from UC and Crohn's disease phase II studies are expected this year, with ongoing studies assessing higher doses for efficacy [44][46] Question: Impact of MFN and organizational changes - Management does not support MFN, emphasizing that price controls could hinder future innovation [53] - Organizational changes focus on enhancing U.S. marketing and maintaining a strong oncology business unit [55] Question: Entyvio sales trends and IRA impact - Q3 sales performance was strong, with improved coverage in the U.S. [60] - The company is preparing for potential price negotiations under the IRA, with uncertainty regarding the extent of price cuts [62][63] Question: Takhzyro growth and competitive impact - Takhzyro continues to be the gold standard for HAE patients, but recent competitive entrants have impacted new starts [67] - Long-term efficacy data supports Takhzyro's market position despite current challenges [68]

Financial Data and Key Metrics Changes - Revenue for the nine-month period was just over JPY 3.4 trillion, a decrease of 3.3% or -2.8% at constant exchange rate (CER) [10] - Core Operating Profit (Core OP) was JPY 971.6 billion, a year-on-year decrease of 3.4% at both actual effects and CER [10] - Reported operating profit was JPY 422.4 billion, an increase of 1.2% [11] - Core EPS was JPY 428, and reported EPS was JPY 137 [11] - Adjusted free cash flow was JPY 625.9 billion, even after a $1.2 billion upfront payment to Innovent Biologics [11] Business Line Data and Key Metrics Changes - Growth and launch products represented over 50% of total revenue and grew 6.7% at CER, an improvement from the 5% growth rate in Q1 and Q2 [11] - In Gastroenterology (GI), Entyvio grew 7.4% at CER, with strong growth in Q3 due to a one-time gross-to-net drop [12] - In rare diseases, Takhzyro slowed to 2.4% growth at CER, impacted by new competing products in the US [12] - Immunoglobulin (IG) growth was 4.3% year to date, driven by subcutaneous IG products, while IVIG sales were impacted by Medicare Part D redesign [13] - In oncology, Perzaca continues to expand with global launches, and vaccine Qdenga growth accelerated to 22.1%, driven primarily by Brazil [14] Market Data and Key Metrics Changes - Entyvio Pen is now on the formulary with all three large pharmacy benefit managers, achieving commercial coverage of more than 80% [12] - The decline in Vyvanse was heavily weighted to the first half of the year, with growth and launch products performing better in the second half [15] - The overall market for Takhzyro has matured, with high diagnosis rates and penetration of prophylaxis treatment [68] Company Strategy and Development Direction - The company is preparing for significant new product launches, focusing on Oveporexin, rusfertide, and zasocitinib, expected to launch over the next 18 months [6][24] - The company aims to maintain operational efficiency while investing in R&D and new product launches [16] - A strategic partnership with Innovent Biologics has added new assets to the pipeline, enhancing growth potential [8] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the significant impact of Vyvanse generic erosion but noted strong cost discipline to limit its impact on profit [10] - The company is revising revenue guidance to a low single-digit decline at CER due to stronger than anticipated Vyvanse generic erosion [17] - Management remains committed to operational efficiency while investing in necessary launches for long-term growth [16] Other Important Information - The transition of leadership to Julie Kim, CEO-elect, is underway, with a focus on maintaining momentum and preparing for upcoming launches [30][32] - The company is implementing organizational changes to enhance competitiveness and speed in the market [32] Q&A Session Summary Question: Thoughts on next fiscal year and dividend policy - Management indicated it is too early to provide guidance for the next fiscal year, with the budget being finalized [41] - The company aims to maintain a progressive dividend policy, considering core EPS and cash flow [44] Question: Zasocitinib phase 2 outcomes and safety data - Data from UC and Crohn's disease phase 2 studies are expected this year, with ongoing studies assessing dosing [46] - The safety profile for psoriasis is consistent with previous studies, with further data to be presented at an upcoming medical conference [47] Question: Impact of MFN and organizational changes - Management does not support MFN due to its potential impact on innovation and is evaluating its effects on the company [54] - Organizational changes are focused on enhancing marketing and sales excellence, particularly in the US market [56] Question: Entyvio sales performance and IRA impact - Entyvio's Q3 performance was strong, with improved coverage in the US, and management is optimistic about sustaining growth [61] - The impact of IRA price negotiations on Entyvio is being assessed, with uncertainty regarding potential price cuts [65] Question: Takhzyro growth and competitive impact - Takhzyro's growth has slowed due to competition and Medicare Part D redesign, but it remains the gold standard for HAE patients [68] - Long-term efficacy data supports Takhzyro's position in the market despite recent competitive entrants [69] Question: PDT clinical progress and Zasocitinib data presentation - Demand for PDT has slowed, particularly in albumin due to regulatory changes in China, but growth is expected to return [86] - Zasocitinib phase III data may be presented at AAD, focusing on its fast onset of action and strong safety profile [90]

Financial Data and Key Metrics Changes - Revenue for the nine-month period was just over JPY 3.4 trillion, a decrease of 3.3% or -2.8% at constant exchange rate [10] - Core Operating Profit was JPY 971.6 billion, a year-on-year decrease of 3.4% at both actual effects and constant exchange rate [10] - Reported operating profit was JPY 422.4 billion, an increase of 1.2% [11] - Core EPS was JPY 428, and reported EPS was JPY 137 [11] - Adjusted free cash flow was JPY 625.9 billion, even after a $1.2 billion upfront payment to Innovent Biologics [11] Business Line Data and Key Metrics Changes - Growth and launch products represented over 50% of total revenue and grew 6.7% at constant exchange rate [11] - In GI, Entyvio grew 7.4% at constant exchange rate, with strong growth in Q3 due to a one-time gross-to-net drop [12] - Rare diseases product Takhzyro slowed to 2.4% growth at constant exchange rate, impacted by new competing products in the US [12] - Immunoglobulin growth was 4.3% year to date, driven by subcutaneous IG products [13] - Qdenga growth accelerated to 22.1%, primarily driven by Brazil [13] Market Data and Key Metrics Changes - Entyvio Pen is now on formulary with all three large pharmacy benefit managers, achieving commercial coverage of more than 80% [12] - Takhzyro's growth is being offset by new competitors and the impact of Medicare Part D redesign in the U.S. [13] - Albumin has returned to growth of 1.3%, but slower than expected due to softening demand in China [13] Company Strategy and Development Direction - The company is preparing for significant new product launches, focusing on Oveporexin, rusfertide, and zasocitinib, expected to launch over the next 18 months [5][6] - The late-stage pipeline includes eight programs with potential to transform the standard of care [8] - The company is committed to maintaining operational efficiency while investing in R&D for future growth [15] Management's Comments on Operating Environment and Future Outlook - Management revised revenue guidance to low single-digit decline at constant exchange rate due to stronger than anticipated Vyvanse generic erosion [16] - The company maintains full-year guidance for core operating profit and core EPS [16] - Management emphasized the importance of cost discipline while preparing for new product launches [15] Other Important Information - The transition of leadership to Julie Kim, CEO-elect, is underway, with operational responsibilities being handed over [28][30] - The company is focusing on simplifying processes and adopting advanced technologies [31] Q&A Session Summary Question: Thoughts on next fiscal year and dividend policy - Management indicated it is too early to provide guidance for the next fiscal year, with the budget being finalized [39] - Emphasis on maintaining a progressive dividend policy, with decisions based on core EPS and cash flow [43] Question: Zasocitinib phase 2 outcomes and safety data - Data from UC and Crohn's disease phase 2 studies expected this year, with ongoing studies on dosing [45] - Safety profile consistent with previous studies, with more data to be presented at an upcoming medical conference [46] Question: Impact of MFN on U.S. policy - Management does not support MFN, emphasizing that price controls could impact future innovation [52] - Organizational changes aim to enhance competitiveness and speed in U.S. marketing [54] Question: Entyvio sales performance and IRA impact - Q3 sales were robust, with improved coverage in the U.S. [59] - Anticipation of price negotiations under IRA, with uncertainty on the extent of potential price cuts [61] Question: Takhzyro growth trends and competitive impact - Takhzyro remains the gold standard, but growth is impacted by new competitors and Medicare Part D redesign [66] - Long-term efficacy data supports Takhzyro's position in the market [66] Question: PDT clinical progress and outlook - Demand slowdown noted, particularly in albumin due to regulatory changes in China [81] - Overall outlook for PDT remains mid-single-digit growth for the year [81] Question: Zasocitinib phase III data presentation - Presentation at AAD is a possibility, with focus on fast onset of action and clear skin [87] - Competitive advantages include ease of administration and strong safety profile [88]

TSE: 4502 Committed to Growth & Shareholder Returns FY2025 Q3 Earnings Announcement The companies in which Takeda directly and indirectly owns investments are separate entities. In this presentation, "Takeda" is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words "we", "us" and "our" are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifyi ...

Core Viewpoint - Takeda announced improved earnings results for Q3 FY2025, highlighting a narrowing gap between incremental Growth & Launch Products revenue and VYVANSE erosion, alongside operational efficiencies leading to reduced operating expenses [1] Financial Performance - The company reported year-on-year reductions in operating expenses, including R&D, indicating effective cost management strategies [1] - Takeda raised its full-year forecasts, attributing this to cost discipline and favorable foreign exchange (FX) conditions [1] Revenue Management - The narrowing gap between Growth & Launch Products revenue and VYVANSE erosion suggests a positive trend in product performance and revenue management [1]

Group 1 - Halozyme Therapeutics Inc. is identified as a promising mid-cap growth stock, with TD Cowen raising its price target from $79 to $90 while maintaining a Buy rating [1] - Investor sentiment is shifting positively ahead of Q4 2025 earnings, with 2026 guidance being crucial for positioning in a sector-wide recovery [1][3] - A global collaboration and exclusive license agreement was announced between Takeda and Halozyme, granting Takeda access to Halozyme's ENHANZE drug-delivery technology for vedolizumab [2][3] Group 2 - The agreement allows Takeda to utilize Halozyme's recombinant human hyaluronidase PH20 enzyme to enhance the subcutaneous delivery of vedolizumab, aiming to improve treatment flexibility and reduce therapy management time [3] - Halozyme is a biopharmaceutical company focused on researching, developing, and commercializing proprietary enzymes and devices both in the US and internationally [4]

Core Viewpoint - Takeda has announced the U.S. availability of GAMMAGARD LIQUID ERC, a new liquid immunoglobulin therapy for individuals aged two years and older with primary immunodeficiency, which is approved as a replacement therapy [1] Group 1: Product Details - GAMMAGARD LIQUID ERC is an immune globulin infusion with a low immunoglobulin A (IgA) content of less than or equal to 2 µg/mL in a 10% solution [1] - The product does not require reconstitution, making it convenient for patients [1]

Core Insights - Halozyme Therapeutics, Inc. will host an Investor Conference Call on January 28, 2026, to discuss preliminary unaudited full year 2025 revenue results, updated financial guidance for 2026-2028, and a business update [1] Group 1: Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through innovative drug delivery solutions [3] - The company is known for its ENHANZE drug delivery technology, which facilitates subcutaneous delivery of injected drugs, impacting over one million patients through ten commercialized products across more than 100 global markets [3] - Halozyme has partnerships with leading pharmaceutical companies, including Roche, Takeda, Pfizer, and others, to utilize its drug delivery technology [3] Group 2: Product Development - Halozyme is developing Hypercon™, a microparticle technology aimed at enhancing drug concentration and reducing injection volume, which broadens the scope of therapeutics for subcutaneous delivery [4] - The company also focuses on drug-device combination products using advanced auto-injector technologies to improve patient comfort and adherence [5] - Halozyme has two proprietary commercial products, Hylenex and XYOSTED, along with partnered commercial products and ongoing development programs with Teva Pharmaceuticals and McDermott Laboratories Limited [5] Group 3: Corporate Information - Halozyme is headquartered in San Diego, California, with additional offices in Ewing, New Jersey; Minnetonka, Minnesota; and Boston, Massachusetts [6]

Core Insights - Halozyme Therapeutics, Inc. (NASDAQ:HALO) is recognized as one of the top new stocks to buy in Ray Dalio's portfolio, with TD Cowen raising its price target from $79 to $90 while maintaining a Buy rating, indicating strong performance and positive outlook for the company [1] Group 1: Financial Performance and Projections - TD Cowen believes that forecasts regarding ongoing ENHANZE launches are overly conservative, suggesting that additional resources in late-stage development will likely enhance the momentum of the company's subcutaneous medication delivery technology [2] - The company is expected to improve its multi-year outlook following strong performance in recent quarters [1] Group 2: Strategic Partnerships - Halozyme Therapeutics has entered into a global collaboration and exclusive licensing agreement with Takeda for its ENHANZE drug delivery technology, which includes an upfront payment and potential future milestone payments from Takeda [3] - The agreement stipulates that Halozyme will receive royalties ranging from low to mid single digits on sales of products that include vedolizumab in conjunction with ENHANZE [3] Group 3: Company Overview - Halozyme Therapeutics is a biopharmaceutical technology platform company focused on developing, manufacturing, and commercializing drug-device combination products utilizing advanced auto-injector technology [4]

Novavax Conference Call Summary Company Overview - **Company**: Novavax - **Industry**: Biotechnology, specifically focusing on vaccines and immunotherapeutics Key Points and Arguments Vision and Transformation - Novavax aims to create a significant impact on global health through its technology platform, aspiring to reach billions of people [4][2] - The company has undergone a transformation since 2023, shifting from a focus solely on its COVID-19 vaccine to a broader growth strategy [5][4] Financial Restructuring - Upon the CEO's arrival in 2023, Novavax had an annual expense run rate of approximately $1.7 billion, 2,600 employees, and $2.5 billion in liabilities, with less than $1 billion in cash [5][6] - The company successfully reduced liabilities by over $2 billion and cut annual expenses by over $1 billion, along with a significant reduction in headcount [6][5] New Growth Strategy - Launched in 2025, the new strategy focuses on partnerships and R&D innovation, aiming for non-GAAP profitability by 2028 [9][8] - The strategy includes leveraging existing partnerships and seeking new collaborations to enhance the technology platform [9][10] Partnerships and Revenue Streams - Current partnerships with Sanofi, Takeda, and Serum Institute of India are expected to generate significant revenue through milestones and royalties [12][19] - Novavax has already earned over $800 million in non-dilutive capital from its partnership with Sanofi [12][13] - The company anticipates additional milestones from Sanofi's combination vaccines, potentially totaling $350 million [35][13] Market Potential - The global vaccine market is projected to grow from approximately $57 billion in 2024 to over $60 billion in the next few years, while the oncology market for immunotherapeutics is expected to grow from $12 billion in 2024 to over $42 billion by 2032 [21][22] - Novavax's technology, particularly the Matrix-M adjuvant, is positioned to tap into these growing markets [22][23] Cost Management and Profitability Path - Novavax aims to reduce SG&A and R&D expenses to $250 million by 2027, with a break-even point of approximately $225 million [26][44] - The company has maintained a strong cash position, ending the third quarter with approximately $810 million, providing a runway into 2028 [44][45] Future Outlook - The company plans to announce more partnerships and pre-clinical data in 2026, with products potentially entering clinical trials as early as 2027 [20][21] - Novavax is optimistic about the durability of the COVID-19 vaccine market, expecting continued demand despite market fluctuations [40][41] Additional Important Information - The company has emphasized a lean operating model and fiscal discipline across its operations to ensure sustainability and growth [45][46] - There is a strong focus on R&D to explore new applications of their technology, particularly in oncology [11][22] - The CEO expressed excitement about the increasing interest in Novavax's technology from other companies, indicating a shift in perception from a COVID-focused narrative to a broader potential [29][30]